Double attack on SARS

August 28, 2012
Double attack on SARS
© Thinkstock

After the SARS-CoV (severe acute respiratory syndrome coronavirus) outbreak in 2003, academia experts in immunology and molecular biology joined forces with industrial vaccine production experts in order to develop preventive and therapeutic measures for SARS.

Despite the fatality of the SARS-CoV outbreak in Asia, the rising and quarantine measures managed to contain viral spread. However, it is believed that the SARS-CoV has not been fully eradicated and as a result, a vaccine as well as an immediate and effective are much needed.

To this end, scientists on the EU-funded 'Immunoprevention and immunotherapy of SARS infection' (Sarsvac) project proposed to follow a vaccination approach coupled with an immunotherapeutic regimen.

More specifically, the strategy for vaccine development consisted of two parallel approaches: the preparation of a classical vaccine made with attenuated SARS-CoV and the identification of potentially immunogenic viral antigens. These antigens were planned to be expressed in a vector-based vaccine for generating specific immunity against the virus.

Additionally, partners studied SARS-CoV–derived virus-like particles (VLPs) in order to understand the morphogenesis and maturation of virions. The information they obtained allowed them to identify specific epitopes that offered protective T and B cell-mediated immunity.

As an immunotherapeutic strategy, neutralising to SARS-CoV were developed and validated. The plan was to administer these as a treatment option to patients already infected with the virus.

The Sarsvac approach promises an immediate and long-term protection against a potential SARS-CoV infection. Commercial exploitation of this vaccine and immunotherapy combination may prove the solution against a future SARS-CoV outbreak.

Related Stories

Recommended for you

New cellular approach found to control progression of chronic kidney disease

December 15, 2017
Researchers have demonstrated for the first time that extracellular vesicles - tiny protein-filled structures - isolated from amniotic fluid stem cells (AFSCs) can be used to effectively slow the progression of kidney damage ...

Testing shows differences in efficacy of Zika vaccines after one year

December 15, 2017
(Medical Xpress)—A large team of researchers with members from Harvard Medical School, Walter Reed Army Institute of Research, Bioqual Inc. and MIT has found that the efficacy of the three types of Zika vaccines currently ...

How to regulate fecal microbiota transplants

December 15, 2017
(Medical Xpress)—A small team of researchers at the University of Maryland, some with affiliations to the Veterans Affairs Maryland Health Care System, has written and published a Policy Forum piece in the journal Science ...

Screening could catch a quarter of hip fractures before they happen

December 15, 2017
Community screening for osteoporosis could prevent more than a quarter of hip fractures in older women - according to new research led by the University of East Anglia (UEA).

Urine test developed to test for tuberculosis

December 14, 2017
(Medical Xpress)—An international team of researchers has developed a urine test that can be used to detect tuberculosis (TB) in human patients. In their paper published in Science Translational Medicine, the group describes ...

40 years after first Ebola outbreak, survivors show signs they can stave off new infection

December 14, 2017
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks, according to a new study ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.